Novanta (NOVT) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $236M, up 2.8% year-over-year, exceeding guidance, driven by the Motion Solutions acquisition despite a 5.3% organic decline.

• Adjusted EBITDA was $51M, above expectations and nearly flat year-over-year; operating cash flow grew 57% to $41M.

• Net income for Q2 was $13.8M, with adjusted EPS of $0.73 and GAAP EPS of $0.38, both down from last year due to higher costs and interest expense.

• Strong performance in medical device markets and new product launches offset by ongoing weakness in life sciences and industrial capital spending.

• Integration of Motion Solutions progressing well; restructuring program underway to reduce operating complexity.

Financial highlights

• Adjusted gross margin was 47% in Q2, flat year-over-year; GAAP gross margin was 44.0%, impacted by product mix and acquisition charges.

• Adjusted EPS for Q2 was $0.73, down from $0.80 last year; diluted GAAP EPS was $0.38.

• Gross debt at quarter-end was $485M, with net debt $387M; leverage ratio at 2.21–2.4x.

• Bookings grew 12% sequentially; book-to-bill improved to 0.95.

• Operating cash flow for the first half of 2024 was $73.9M, up from $36.4M in the prior year.

Outlook and guidance

• Full-year 2024 revenue expected at the low end of prior guidance (~$975M), with >10% reported growth and ~2% organic growth.

• Q3 2024 revenue guidance: $241M–$244M, with 1–2% organic growth year-over-year.

• Adjusted EBITDA for 2024 expected at $215M–$222M, with >23% margin in H2.

• Adjusted EPS for 2024 guided to $3.20–$3.35, raising the lower end by $0.10.

• Management expects to complete the 2024 restructuring program by year-end, with $3–4M in additional charges.